News
19h
Health on MSNThis New Pill Could Rival Ozempic and Wegovy—Will It Make Weight Loss Drugs More Accessible?Eli Lilly plans to pursue approval for its new GLP-1 pill by the end of this year. Fact checked by Nick Blackmer A daily pill ...
Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.
Patients who stop using weight loss medications are likely to return to their baseline weight within two years, a new ...
Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...
The global weight-loss drug market, once dominated by Novo Nordisk, is undergoing a dramatic transformation. On Friday, the ...
The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...
A North Texas woman with a cautionary tale warns others to do their research before starting popular weight loss drugs.
Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...
As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...
Trump signs executive order, discussed "overweight" friend who was taking the "fat shot drug." It wasn't confirmed whether he meant Ozempic or Wegovy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results